These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20657286)

  • 21. Practice variation: the Achilles' heel in quality cancer care.
    Dilts DM
    J Clin Oncol; 2005 Sep; 23(25):5881-2. PubMed ID: 16087953
    [No Abstract]   [Full Text] [Related]  

  • 22. Surveillance testing among survivors of early-stage breast cancer.
    Keating NL; Landrum MB; Guadagnoli E; Winer EP; Ayanian JZ
    J Clin Oncol; 2007 Mar; 25(9):1074-81. PubMed ID: 17369571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The treated natural history of high risk superficial bladder cancer: 15-year outcome.
    Cookson MS; Herr HW; Zhang ZF; Soloway S; Sogani PC; Fair WR
    J Urol; 1997 Jul; 158(1):62-7. PubMed ID: 9186324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Which physician and practice characteristics are associated with adherence to evidence-based guidelines for depressive and anxiety disorders?
    Smolders M; Laurant M; Verhaak P; Prins M; van Marwijk H; Penninx B; Wensing M; Grol R
    Med Care; 2010 Mar; 48(3):240-8. PubMed ID: 20125045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence-based medicine and practice guidelines: application to genetics.
    Toriello HV; Goldenberg P
    Am J Med Genet C Semin Med Genet; 2009 Aug; 151C(3):235-40. PubMed ID: 19621463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variation in the management of early breast cancer in rural and metropolitan centres: implications for the organisation of rural cancer services.
    Craft PS; Buckingham JM; Dahlstrom JE; Beckmann KR; Zhang Y; Stuart-Harris R; Jacob G; Roder D; Tait N
    Breast; 2010 Oct; 19(5):396-401. PubMed ID: 20452216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of superficial bladder cancer with intravesical perfusion of rIL-2: a follow-up study.
    Ferlazzo G; Magno C; Iemmo R; Rizzo M; Lupo G; Semino C; Bruno S; Melioli G
    Anticancer Res; 1996; 16(2):979-80. PubMed ID: 8687163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma].
    Stenzl A; Cowan NC; De Santis M; Jakse G; Kuczyk MA; Merseburger AS; Ribal MJ; Sherif A; Witjes JA;
    Actas Urol Esp; 2010 Jan; 34(1):51-62. PubMed ID: 20223133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved guideline adherence to pharmacotherapy of chronic systolic heart failure in general practice--results from a cluster-randomized controlled trial of implementation of a clinical practice guideline.
    Peters-Klimm F; Müller-Tasch T; Remppis A; Szecsenyi J; Schellberg D
    J Eval Clin Pract; 2008 Oct; 14(5):823-9. PubMed ID: 19018915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy.
    Weiss C; Wittlinger M; Engehausen DG; Krause FS; Ott OJ; Dunst J; Sauer R; Rödel C
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1502-6. PubMed ID: 17935905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Earlier use of aggressive therapy could prevent one-third of bladder cancer deaths.
    Pinkowish MD
    CA Cancer J Clin; 2009; 59(3):142-4. PubMed ID: 19369683
    [No Abstract]   [Full Text] [Related]  

  • 32. Management of invasive bladder cancer.
    Parker CC; Huddart RA
    Br J Hosp Med; 1996 Sep 4-17; 56(5):213-8. PubMed ID: 8879700
    [No Abstract]   [Full Text] [Related]  

  • 33. Follow-up of nonmuscle invasive transitional cell carcinoma of the bladder: how and how often?
    Schmidbauer J; Lindenau G
    Curr Opin Urol; 2008 Sep; 18(5):504-7. PubMed ID: 18670275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Surveillance and prognosis of "Ta" superficial tumors of the bladder. Homogeneous series of 138 cases followed for 1 to 18 years].
    Lachand AT; Texier J; Texier P
    Prog Urol; 2001 Jun; 11(3):466-71. PubMed ID: 11512459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer.
    Kulkarni GS; Hakenberg OW; Gschwend JE; Thalmann G; Kassouf W; Kamat A; Zlotta A
    Eur Urol; 2010 Jan; 57(1):60-70. PubMed ID: 19740595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Point. Routine use of postoperative intravesical chemotherapy after TURBT-should it be done?
    Soloway MS; Arianayagam M
    Urology; 2010 Oct; 76(4):794-6. PubMed ID: 20932403
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Follow-up recommendations for patients after curative treatment of invasive breast cancer].
    Zuber M; Viehl CT; Güller U; Langer I
    Ther Umsch; 2008 Jun; 65(6):319-21. PubMed ID: 18622954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition).
    Rubins J; Unger M; Colice GL;
    Chest; 2007 Sep; 132(3 Suppl):355S-367S. PubMed ID: 17873180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Follow-up: the evidence.
    D'Ugo D; Biondi A; Tufo A; Persiani R
    Dig Surg; 2013; 30(2):159-68. PubMed ID: 23867593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.